Hikma Pharmaceuticals PLC (HIK.L,HIK) said on Thursday that it has reaffirmed its annual guidance, citing an encouraging start to 2026.
For fiscal 2026, Hikma anticipates operating profit of $720 million to $770 million, with revenue growth of 2% to 4%.
For fiscal 2025, the Group had posted an operating profit of $542 million, with revenue of $3.349 billion.
Commenting on the global geopolitical environment, the Group said: "We are monitoring the evolving geopolitical situation in the Middle East. Demand in the region remains robust and the Group continues to maintain sufficient inventory levels to mitigate potential supply chain disruptions. To date we have experienced some inflationary pressure, particularly linked to shipping, energy and insurance costs."
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.